论文部分内容阅读
背景:采用培哚普利降低稳定性冠心病患者心脏事件的欧洲试验(EUROPA)最近已报道。目的:评价培哚普利在英国用于稳定性冠心病患者时的成本效益。方法:临床和原始应用数据均来自EUROPA试验。成本包括药物和住院费用。健康相关的生活质量值来自已发表的文献。成本效益分析是主要事件(非致死性心肌梗死、心脏停搏或心血管性死亡)风险的函数,
BACKGROUND: A European trial of perindopril to reduce cardiac events in patients with stable coronary heart disease (EUROPA) has recently been reported. OBJECTIVE: To evaluate the cost-effectiveness of perindopril in the UK in patients with stable coronary artery disease. METHODS: Clinical and primary application data were from the EUROPA trial. Costs include medication and hospitalization costs. Health-related quality of life values come from published literature. Cost-benefit analysis is a function of the risk of a major event (nonfatal myocardial infarction, cardiac arrest, or cardiovascular death)